A Controlled Study of Lysergide in the Treatment of Alcoholism. I. The Effects on Drinking Behavior
The DOI matches its Crossref record.
Abstract
To investigate the effects of lysergide treatment on the drinking behavior of alcoholics, 30 alcoholics (2 women), aged between 26 and 50 years (average 40), all with a long history of excessive drinking and previous unsuccessful attempts at therapy, were randomly selected from the inpatient facility of the Toronto clinic of the Alcoholism and Drug Addiction Research Foundation of Ontario. They were divided into 3 groups: 10 received a single 800-µg dose of lysergide before an investigative and therapeutic interview, 10 received 60 mg of ephedrine sulfate before a similar interview and 10 received no drug. All patients were given psychiatric interviews, psychological tests and a drinking behavior questionnaire prior to the study and again in a follow-up 6 months later. All patients took part in the general treatment program of the clinic, which included group, physio- and occupational therapy and individual casework and psychiatric interviews. The average length of stay after the drug session was 1 week. Assignment to groups was made so that the patients, the therapists and the follow-up workers were unaware which drug was given; however, the therapist giving the drugs guessed correctly in 19 out of 20 cases. Thus, this was a modified single-blind study. All three groups showed an improvement at the 6-month follow-up, but with no significant intergroup differences. The gain in abstinence time in the lysergide, ephedrine and control groups, respectively, was 34%, 32% and 20%; the number of times patients had one or more drinks pretreatment was 14, 23 and 19, and post-treatment, 5, 11 and 7; the number of times patients got drunk pretreatment was 6, 3 and 11, and post-treatment, 3, 3 and 3. No significant intergroup differences were found in the following alcoholic symptoms: morning drinking, blackouts, drinking on job, or preoccupation with alcohol. It is concluded that lysergide, as used in the present study, failed as an effective adjunct to psychotherapy, in contrast to the claims made in previous studies. It is suggested that the discrepancy with the earlier reports can be explained by the controlled nature of the present study and possibly by such factors as the personnel and facilities employed or details of procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
“…research area from the 1950s through 1970s involved the therapeutic use of 5-HT2AR agonist hallucinogens in the treatment of drug dependence, including alcohol and opioid dependence (Chwelos et al., 1959; Hollister et al., 1969; Ludwig et al., 1969; Savage and McCabe, 1973; Smart et al., 1966).”
BackgroundInfluentialBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
“Participants were male inpatients, except for two females and a small number of day-care patients in one of the trials (Smart et al., 1966).”
BackgroundMethodResultInfluentialPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
The cost effectiveness of treatment for alcoholism: a first approximation
Holder, H., Longabaugh, R., Miller, W. R., & Rubonis, A. V. (1991) · Journal of Studies on Alcohol · doi:10.15288/jsa.1991.52.517 · Cited by 394
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
“Smart et al, in 1966, reported the effect of a single LSD experience under controlled conditions on the behaviour of 30 alcoholics who were either inpatients or outpatients in Toronto, Canada(Smart et al., 1966).”
BackgroundInfluentialAdverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
Potential Therapeutic Effects of Psilocybin
Johnson, M. W., & Griffiths, R. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0542-y · Cited by 296
The Effectiveness of Alcoholism Treatment
Miller, W. R., & Hester, R. K. (1986) · Treating Addictive Behaviors · doi:10.1007/978-1-4613-2191-0_7 · Cited by 276
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“For instance, one study of LSD for the treatment of alcoholism administered high doses (i.e., 800 !g) of the drug to patients strapped to a hospital bed, and without prior preparation (Smart et al., 1966).”
BackgroundMethodTherapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Psychedelics and psychotherapy
Nayak, S., & Johnson, M. W. (2021) · Pharmacopsychiatry · doi:10.1055/a-1312-7297 · Cited by 71
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65
“A RCT showed positive results in which patients were strapped to a bed in a hospital room [51], also suggesting that the effect of psychedelics on alcohol misuse may have involved a pharmacological component distinct from psychotherapeutic care and setting.”
BackgroundLSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38
“…as treatment for AUD are varied, including an RCT reporting positive results in which patients were strapped to a bed in a hospital room (Smart et al., 1966), suggesting that the effect of LSD on alcohol misuse may have involved a pharmacological determinant distinct from…”
BackgroundO'Donnell, K. C., Mennenga, S. E., Owens, L. T., Podrebarac, S. K., Baron, T., Rotrosen, J., Ross, S., Forcehimes, A. A., & Bogenschutz, M. P. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106976 · Cited by 23
Metadata
- Authors
- Smart, R. G., Storm, T., Baker, E. F. W., & Solursh, L.
- Venue
- Quarterly Journal of Studies on Alcohol
- Publisher
- Alcohol Research Documentation, Inc.
- Published
- 1966-09-01
- Volume
- 27
- Issue
- 3
- Pages
- 469-482
- ISSN
- 0033-5649 (ISSN-L)
- 1946-7214
- OpenAlex
- W2243916050
- Cited by
- 100
- References
- 0
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.